PRCT Stock Forecast & Price Target

PROCEPT BioRobotics is well-positioned to achieve durable, double-digit sales growth in the next decade, with their innovative AquaBeam Robotic System offering a novel approach to the large and underpenetrated BPH surgical market. While their initial focus is on the ~$900mn sub-segment of resective surgery in the US, there is potential for the company to tap into a theoretical headroom of ~$25bn when considering all men undergoing BPH treatment, including therapeutics. The recent lowering of FY26 revenue guidance was mainly due to inventory management and tariff-related headwinds, and the company remains bullish on their international growth potential, which currently accounts for about 10% of revenue but could increase to 20% or more in the future.

PROCEPT BioRobotics is facing several challenges in its business, including a recently implemented reorganization of its sales force which is causing a short-term disruption in commercial activities, uncertainty surrounding near-term shift in handpiece purchasing patterns, potential pricing pressure on its products, and the possibility of increased competition in the BPH market. This has resulted in a decrease in price target to $30, with an outlook for breakeven profitability and slower revenue growth in the near-term. Furthermore, the company's high capital expenses for its robotics systems are facing pressure from hospitals facing financial challenges, potentially impacting future sales and guidance.